Takeda Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on Overall Health-Related Quality of Life for ALUNBRIG® (brigatinib)

– Phase 1/2 Data Being Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrated TAK-788 Extended the Time Until Disease Progression or Death by More Than Seven Months –

– Takeda’s Growing Lung Portfolio is Driven by a Dedication to Developing Innovative Therapies for People Living with NSCLC –

CAMBRIDGE, MA, USA & OSAKA, Japan I June 03, 2019 I Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that new data for TAK-788 will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 3 at 10:12 a.m. CT in Chicago. Results from a Phase 1/2 first-in-human, open-label, multicenter study showed TAK-788 yielded a median progression-free survival (PFS) of 7.3 months and a confirmed objective response rate (ORR) of 43% in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These findings add to the collection of data featured at this year’s meeting from Takeda’s lung cancer portfolio, which also revealed key insights from sub-analyses of ALUNBRIG (brigatinib), including quality of life data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial. TAK-788 is an investigational drug for which efficacy and safety have not been established. ALUNBRIG does not yet have regulatory approval for first-line therapy.

“We are thrilled to share promising, early results from TAK-788, an investigational therapy that has the potential to help advance the treatment of NSCLC patients with EGFR exon 20 insertion mutations,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “Furthermore, meaningful insights from our ongoing ALUNBRIG Phase 3 clinical trial, ALTA-1L, will be unveiled during the meeting. ALUNBRIG is the only treatment of its kind to report improved quality of life over another ALK tyrosine kinase inhibitor (TKI) as evidenced by patient-reported outcomes presented at ASCO. These findings build upon our ALTA-1L efficacy data and illustrate ALUNBRIG’s potential to provide a meaningful benefit for patient’s life quality.”

Results from the Phase 1/2 trial of TAK-788 will be presented on Monday, June 3 at 10:12 a.m. CT in Hall B1 of the McCormick Place Convention Center. A summary of key findings is provided below:

  • The current analysis evaluated a total of 28 NSCLC patients with EGFR exon 20 insertions who were treated with the recommended Phase 2 dose (RP2D) of 160 mg once daily. More than 50% of patients had received three or more prior regimens and 61% had been previously treated with an immune-checkpoint inhibitor. The median time on treatment was 7.9 months ongoing.
  • Among the total patients treated, including those with brain metastases at baseline, 43% (n=12/28) had a confirmed objective response and median PFS was 7.3 months. Patients without brain metastases at baseline had a confirmed objective response of 56% (n=9/16) and a median PFS of 8.1 months.
  • The disease control rate was 86% (n=24/28) for the total patients treated and 100% for patients without brain metastases at baseline (n=16/16).
  • The safety profile of TAK-788 was manageable. For patients treated at the 160 mg once daily dose:
    • The most common any grade treatment-related adverse events (AEs) were diarrhea (85%), nausea (43%), rash (36%), vomiting (29%) and decreased appetite (25%).
    • Most treatment-related AEs were Grade 1-2 and reversible.
    • Forty percent experienced Grade ≥3 treatment-related AEs.
    • The most common Grade ≥3 treatment-related AEs were diarrhea (18%), nausea (6%), increased lipase (6%), increased amylase (4%) and stomatitis (4%).
    • Food instructions have been included in the ongoing study with the potential to improve gastrointestinal tolerability.
  • At the time of the analysis, 50% of patients were still on treatment, and additional results will be presented at future congresses, including those from the recently opened Phase 2 pivotal extension cohort, EXCLAIM. The pivotal cohort was designed to evaluate the efficacy and safety of TAK-788 at 160 mg once daily in previously treated patients and will build upon the results seen in the Phase 1/2 trial.

“Results from this Phase 1/2 trial show that TAK-788 effectively treated NSCLC patients whose tumors harbor EGFR exon 20 insertion mutations and who had been previously treated with multiple prior therapies,” said Pasi A Jänne, M.D., Ph.D., Dana-Farber Cancer Institute. “These data represent an important development and demonstrate progress in addressing an unmet need for these patients, who currently have limited treatment options and no approved targeted therapies.”

For ALUNBRIG, Takeda presented three posters featuring results from ongoing trials of its clinical development program, which seeks to expand Takeda’s research of ALUNBRIG and optimize its use among patients with anaplastic lymphoma kinase-positive (ALK+) NSCLC.

Notably, two posters highlighted sub-analyses of the Phase 3 ALTA-1L trial in patients who had not received prior treatment with an ALK inhibitor:

  • Results from an analysis of the validated patient-reported outcomes questionnaire EORTC QLQ-C30 showed that ALUNBRIG significantly improved the overall health-related quality of life (HRQoL) compared to crizotinib. Results also showed improvements for patients receiving ALUNBRIG across functional scales, with significant improvement seen for physical, emotional and cognitive functions. There was also observed improvement for symptom scales including fatigue, nausea and vomiting, appetite loss and constipation.
  • Additionally, an investigation of outcomes in patients of Asian versus non-Asian heritage demonstrated that ALUNBRIG showed improvement in PFS compared to crizotinib for both patient subgroups. The safety profile of ALUNBRIG in these subgroups was consistent with what has been reported previously, with no new safety concerns. These findings add to the body of evidence evaluating ALUNBRIG in the first-line setting for patients with ALK+ NSCLC.

About EGFR Exon 20 Insertion-Mutant NSCLC

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of the estimated 1.8 million new cases of lung cancer diagnosed each year worldwide, according to the World Health Organization.1,2 Epidermal growth factor receptor (EGFR) is one of several unique, genetic alternations found in NSCLC that affects approximately 15-21% of all NSCLC patients.3,4 The exon refers to the location of the EGFR mutations, which can be found in exon 18, 19, 20 or 21. Exon 20 insertions are much less common than EGFR mutations in other exons, comprising approximately 6% of all EGFR-mutated lung tumors.5 Therefore, patients with NSCLC who harbor EGFR exon 20 insertion mutations make up a small proportion of the NSCLC population, and there are currently no targeted therapy options to treat them, as approved EGFR tyrosine kinase inhibitor (TKIs) were not designed for patients with this subtype of EGFR mutations.

About TAK-788

TAK-788 is a potent and selective next-generation, small-molecule tyrosine kinase inhibitor (TKI) intelligently designed and under clinical investigation to inhibit epidermal growth factor receptor (EGFR) and human EGFR 2 (HER2) exon 20 mutations with selectivity over wild type (WT) EGFR. Non-clinical studies demonstrated antitumor activity against de novo mutations in EGFR including EGFR exon 20 insertions and the acquired resistance mutation T790M. In October 2018, the ongoing Phase 1/2 trial of TAK-788 was amended to add the pivotal extension cohort, EXCLAIM, which was designed to evaluate the efficacy and safety of TAK-788 at 160 mg once daily in previously treated patients with EGFR exon 20 insertions and is currently actively recruiting.

The TAK-788 development program has started first in the non-small cell lung cancer (NSCLC) population and is expected to expand to additional underserved populations in other tumor types. TAK-788 is an investigational drug for which efficacy and safety have not been established.

About ALK+ NSCLC

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of the estimated 1.8 million new cases of lung cancer diagnosed each year worldwide, according to the World Health Organization.1,2 Genetic studies indicate that chromosomal rearrangements in anaplastic lymphoma kinase (ALK) are key drivers in a subset of NSCLC patients. Approximately three to five percent of patients with metastatic NSCLC have a rearrangement in the ALK gene.6,7,8

Takeda is committed to continuing research and development in NSCLC to improve the lives of the approximately 40,000 patients diagnosed with this serious and rare form of lung cancer worldwide each year.9

About ALUNBRIG® (brigatinib)

ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) that was designed to target and inhibit the anaplastic lymphoma kinase (ALK) fusion protein in non-small cell lung cancer (NSCLC).

  • In April 2017, ALUNBRIG received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC patients who have progressed on or are intolerant to crizotinib. This indication is approved under Accelerated Approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • In July 2018, Health Canada approved ALUNBRIG for the treatment of adult patients with ALK+ metastatic NSCLC who have progressed on or who were intolerant to an ALK inhibitor (crizotinib).
  • In November 2018, the European Commission (EC) granted marketing authorization for ALUNBRIG as a monotherapy for the treatment of adult patients with ALK+ advanced NSCLC previously treated with crizotinib. The FDA, Health Canada and EC approvals of ALUNBRIG were primarily based on results from the pivotal Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) trial.

ALUNBRIG received Breakthrough Therapy Designation from the FDA for the treatment of patients with ALK+ NSCLC whose tumors are resistant to crizotinib and was granted Orphan Drug Designation by the FDA for the treatment of ALK+ NSCLC, ROS1+ and EGFR+ NSCLC.

The brigatinib clinical development program further reinforces Takeda’s ongoing commitment to developing innovative therapies for people living with ALK+ NSCLC worldwide and the healthcare professionals who treat them. The comprehensive program includes the following clinical trials:

  • Phase 1/2 trial, which was designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ALUNBRIG.
  • Pivotal Phase 2 ALTA trial investigating the efficacy and safety of ALUNBRIG at two dosing regimens in patients with ALK+ locally advanced or metastatic NSCLC who had progressed on crizotinib.
  • Phase 3 ALTA-1L, global, randomized trial assessing the efficacy and safety of ALUNBRIG in comparison to crizotinib in patients with ALK+ locally advanced or metastatic NSCLC who have not received prior treatment with an ALK inhibitor.
  • Phase 2 J-ALTA, single-arm, multicenter trial in Japanese patients with ALK+ NSCLC, focusing on patients who have progressed on alectinib. This trial is now enrolling.
  • Phase 2 ALTA 2, global, single-arm trial evaluating ALUNBRIG in patients with advanced ALK+ NSCLC who have progressed on alectinib or ceritinib. This trial is now enrolling.
  • Phase 3 ALTA 3, global randomized trial comparing the efficacy and safety of ALUNBRIG versus alectinib in participants with ALK+ NSCLC who have progressed on crizotinib. This trial is now enrolling.

For additional information on the brigatinib clinical trials, please visit www.clinicaltrials.gov.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

1 World Health Organization. Latest Global Cancer Data. https://www.who.int/cancer/PRGlobocanFinal.pdf. Accessed May 11, 2019.
2 American Cancer Society. What is Non-Small Cell Lung Cancer? https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed May 11, 2019.
3 Kris MG, et al. JAMA, 2014;311:1998-2006.
4 Chan BA, et al. TranslLung Cancer Res. 2015;4:36-54.
5 Kobayashi Y & Mitsudomi T. Cancer Sci 2016;107:1179–86.
6 Gainor JF, Varghese AM, Ou SH, et al. Clin Cancer Res. 2013;19(15):4273-81.
7 Koivunen JP, Mermel C, Zejnullahu K, et al. Clin Cancer Res. 2008; 14(13):4275-83.
8 Wong DW, Leung EL, So KK, et al. Cancer. 2009; 115(8):1723-33.
9 Chia PL, Mitchell P, Dobrovic A, John T. Clin Epidemiol, 2014;6:423-432.

SOURCE: Takeda Pharmaceutical Co

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top